Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

Author： Lalisang R.   Erdkamp F.   Rodenburg C.   Knibbeler-van Rossum C.   Nortier J.   Bochove A.   Slee P.   Voest E.   Wils J.   Wals J.   Loosveld O.   Smals A.   Blijham G.   Tjan-Heijnen V.   Schouten H.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.128, Iss.2, 2011-07, pp. : 437-445

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

By Kümmel Sherko   Thomas Anke   Paepke Stefan   Schwarz Marion   Heinrich Georg   Wetzel Andrea   Elling Dirk   Kohls Andreas   Lichtenegger Werner   Blohmer Jens-Uwe  

Acta Oncologica, Vol. 44, Iss. 3, 2005-05 ,pp. : 248-254

Informa Healthcare

Access to resources Recommend Favorite

Cisplatin–epirubicin–paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology group (SICOG) phase II study

By Frasci G.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 2, 2000-07 ,pp. : 87-97

Springer Publishing Company

Access to resources Recommend Favorite

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study

By Frasci Giuseppe   Comella Pasquale   D'Aiuto Giuseppe   Budillon Alfredo   Barbarulo Deborah   Thomas Renato   Capasso Immacolata   Casaretti Rossana   Daponte Antonio   Caponigro Francesco   Gravina Adriano   Maiorino Luigi   Caratení Giacomo   Gentile Alfonso   Comella Giuseppe  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 13-26

Springer Publishing Company

Access to resources Recommend Favorite

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

By Hatschek T.   Carlsson L.   Einbeigi Z.   Lidbrink E.   Linderholm B.   Lindh B.   Loman N.   Malmberg M.   Rotstein S.   Söderberg M.   Sundquist M.   Walz T.   Hellström M.   Svensson H.   Åström G.   Brandberg Y.   Carstensen J.   Fernö M.   Bergh J.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 939-947

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study

By Papadimitriou Christos   Papakostas Pavlos   Timotheadou Eleni   Aravantinos Gerasimos   Bamias Aristotelis   Fountzilas George  

Cancer Investigation, Vol. 26, Iss. 5, 2008-06 ,pp. : 491-498

Informa Healthcare

Access to resources Recommend Favorite